Abstract
A prevalent unwanted action of cyclo-oxygenase (COX) inhibitors, as exemplified by the non-steroidal anti-inflammatory drugs (NSAIDs), is their potential to produce gastrointestinal side effects in clinical use. The injury provoked by such agents includes rapid superficial disruption to the surface layer of the gastric mucosa, the production of acute gastric erosions in the corpus region and the formation of ulcers in the antral region of the stomach. The small intestine is also adversely affected, with a developing enteropathy over a more protracted period that causes lesions and inflammation in the gut. From experimental work, the interactive mechanisms of such damage in the stomach differ distinctly from those that underlie the intestinal injury, yet the damage in both regions involves the inhibition of both COX-1 and COX-2 isoforms. This chapter outlines the in vivo methods that can be used to identify the potential for novel NSAIDs and selective COX-inhibitors to produce acute gastric corpus lesions and more-chronic antral ulcers in the rat, as well as causing small intestinal enteropathy. Such methods can also be utilized to evaluate the ability of novel agents to prevent the gastrointestinal injury provoked by NSAIDs or COX-inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
GarcÃa RodrÃguez LA, Barreales Tolosa L (2007) Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 132:498–506
Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C (2003) Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124:288–292
Whittle BJR (2003) Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam Clin Pharmacol 17:301–313
Wallace JL, McKnight W, Reuter B, Vergnolle N (2000) NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119:705–714
Lichtenberger LM, Romero JJ, Dial EJ (2007) Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. Br J Pharmacol 150:913–919
Whittle BJR (2004) Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. Eur J Pharmacol 500:427–439
Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci U S A 91:3228–3232
Whittle BJR, Higgs GA, Eakins KE, Moncada S, Vane JR (1980) Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 284:271–273
Lanas A, Hunt R (2006) Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med 38:415–428
Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP, MEDAL Steering Committee (2007) Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison. Lancet 369:465–473
Henry D, McGettigan P (2007) Selective COX-2 inhibitors: a promise unfulfilled? Gastroenterology 132:790–794
Funk CD, Fitzgerald GA (2007) COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 50:470–479
Whittle BJR (1977) Mechanisms underlying gastric mucosal damage induced by indomethacin and bile-salts, and the actions of prostaglandins. Br J Pharmacol 60:455–460
Konturek SJ, Brzozowski T, Piastucki I, Radecki T, Dembiński A, Dembińska-Kieć A (1982) Role of locally generated prostaglandins in adaptive gastric cytoprotection. Dig Dis Sci 27:967–971
Rainsford KD (1986) Structural damage and changes in eicosanoid metabolites in the gastric mucosa of rats and pigs induced by anti-inflammatory drugs of varying ulcerogenicity. Int J Tissue React 8:1–14
Gyömber E, Vattay P, Szabo S, Rainsford KD (1996) Role of early vascular damage in the pathogenesis of gastric haemorrhagic mucosal lesions induced by indomethacin in rats. Int J Exp Pathol 77:1–6
Gretzer B, Maricic N, Respondek M, Schuligoi R, Peskar BM (2001) Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol 132:1565–1573
Santos CL, Souza MH, Gomes AS, Lemos HP, Santos AA, Cunha FQ, Wallace JL (2005) Sildenafil prevents indomethacin-induced gastropathy in rats: role of leukocyte adherence and gastric blood flow. Br J Pharmacol 146:481–486
Satoh H, Inada I, Hirata T, Maki Y (1981) Indomethacin produces gastric antral ulcers in the refed rat. Gastroenterology 81:719–725
Satoh H, Ligumsky M, Guth PH (1984) Stimulation of gastric prostaglandin synthesis by refeeding in the rat. Role in protection of gastric mucosa from damage. Dig Dis Sci 29:330–335
Robert A (1975) An intestinal disease produced experimentally by a prostaglandin deficiency. Gastroenterology 69:1045–1047
Whittle BJR (1981) Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 80:94–98
Reuter BK, Davies NM, Wallace JL (1997) Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria and enteropathic circulation. Gastroenterology 112:109–117
Evans SM, Whittle BJR (2001) Interactive roles of superoxide and inducible nitric oxide synthase in rat intestinal injury provoked by non-steroidal anti-inflammatory drugs. Eur J Pharmacol 429:287–296
Yokota A, Taniguchi M, Takahira Y, Tanaka A, Takeuchi K (2005) Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats. J Pharmacol Exp Ther 314:302–309
Evans SM, Lazlo F, Whittle BJR (2000) Site-specific lesion formation, inflammation and inducible nitric oxide synthase expression by indomethacin in the rat intestine. Eur J Pharmacol 388:281–285
Evans SM, Whittle BJR (2003) Role of bacteria and inducible nitric oxide synthase activity in the systemic inflammatory microvascular response provoked by indomethacin in the rat. Eur J Pharmacol 461:63–71
Wallace JL, Whittle BJR (1986) Role of mucus in the repair of gastric epithelial damage in the rat. Inhibition of epithelial recovery by mucolytic agents. Gastroenterology 91:603–611
Skeljo MV, Giraud AS, Yeomans ND (1992) Adaptation of rat gastric mucosa to repeated doses of non-salicylate non-steroidal anti-inflammatory drugs. J Gastroenterol Hepatol 7:586–590
Clayton NM, Oakley I, Williams LV, Trevethick MA (1996) The role of acid in the pathogenesis of indomethacin-induced gastric antral ulcers in the rat. Aliment Pharmacol Ther 10:339–345
Acknowledgments
The author is supported by a grant from the William Harvey Research Foundation, London.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Whittle, B.J.R. (2010). Protocols to Assess the Gastrointestinal Side Effects Resulting from Inhibition of Cyclo-Oxygenase Isoforms. In: Ayoub, S., Flower, R., Seed, M. (eds) Cyclooxygenases. Methods in Molecular Biology, vol 644. Humana Press. https://doi.org/10.1007/978-1-59745-364-6_16
Download citation
DOI: https://doi.org/10.1007/978-1-59745-364-6_16
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-58829-953-6
Online ISBN: 978-1-59745-364-6
eBook Packages: Springer Protocols